Drug Overdose - Drugs In Development, 2021

July 2021 | 102 pages | ID: DAB5A39DD637EN
Global Markets Direct

Abstracts

Drug Overdose - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Drugs In Development, 2021, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 1, 4, 3, 8, 3 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
• The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Drug Overdose - Overview
Drug Overdose - Therapeutics Development
Drug Overdose - Therapeutics Assessment
Drug Overdose - Companies Involved in Therapeutics Development
Drug Overdose - Drug Profiles
Drug Overdose - Dormant Projects
Drug Overdose - Discontinued Products
Drug Overdose - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Drug Overdose, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Drug Overdose - Pipeline by Adamis Pharmaceuticals Corp, 2021
Drug Overdose - Pipeline by Amphastar Pharmaceuticals Inc, 2021
Drug Overdose - Pipeline by Avior Bio Inc, 2021
Drug Overdose - Pipeline by Clear Scientific LLC, 2021
Drug Overdose - Pipeline by Crossject SA, 2021
Drug Overdose - Pipeline by Egetis Therapeutics AB, 2021
Drug Overdose - Pipeline by Emergent BioSolutions Inc, 2021
Drug Overdose - Pipeline by Fab’entech SA, 2021
Drug Overdose - Pipeline by Hepione Therapeutics Inc, 2021
Drug Overdose - Pipeline by HitGen Inc, 2021
Drug Overdose - Pipeline by Icure Pharmaceutical Inc, 2021
Drug Overdose - Pipeline by Insys Therapeutics Inc (Inactive), 2021
Drug Overdose - Pipeline by InterveXion Therapeutics LLC, 2021
Drug Overdose - Pipeline by Klaria Pharma Holding AB, 2021
Drug Overdose - Pipeline by Mucodel Pharma LLC, 2021
Drug Overdose - Pipeline by Nasus Pharma Ltd, 2021
Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, 2021
Drug Overdose - Pipeline by Orexo AB, 2021
Drug Overdose - Pipeline by ResQ Pharma Inc, 2021
Drug Overdose - Pipeline by Vallon Pharmaceuticals Inc, 2021
Drug Overdose - Pipeline by Worphmed Srl, 2021
Drug Overdose - Dormant Projects, 2021
Drug Overdose - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Drug Overdose, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021